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 Background 
 Psoriasis is a chronic inflammatory, systemic disease 
that primarily affects the skin. Currently incurable, pso-
riasis can occur at any age  [1] . It is equally distributed 
between men and women, and has a higher prevalence in 
Caucasians compared to African Americans  [2] . With 
about 4.5 million affected adults in the US and estimated 
annual cost per patient between USD 650 and 800 the so-
cioeconomic impact of psoriasis is remarkable  [3, 4] . The 
typical thickened, red, scaly plaques are often disfiguring 
and may cause substantial problems in everyday life  [5] .
 Traditional antipsoriatic treatments include topical 
and systemic immunosuppressive drugs and UV therapy. 
Having been almost exclusively discussed in the derma-
tological literature for several years, the introduction of 
biologics recently evoked some broader notice of psoria-
sis  [6–11] . The fact that most biologics are approved ex-
clusively for moderate-to-severe psoriasis led to a contro-
versial discussion about the definition of severity in pso-
riasis  [12] . Clinically, the severity of psoriasis is described 
by the intensity and extent of the psoriatic lesions  [13, 14] . 
From the patient’s perspective, however, the impact pso-
riasis has on their everyday physical, social, and psycho-
logical-emotional functioning is most important. A sub-
group of patients with objectively mild psoriasis experi-
ences high subjective disease severity  [12] . Health-related 
quality of life (HRQL) describes the perceived influence 
of illness on everyday functioning, the achievement of life 
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 Abstract 
 Background: It has been proposed that depression plays a 
role in how psoriasis affects quality of life. However, primary 
data are limited.  Objective: To investigate the role depres-
sion plays in how patients experience psoriasis.  Methods: 
Cross-sectional study conducted between January and May 
2005. Recruitment of 265 adults with prevalent psoriasis 
through Internet advertisements. Standardized assessment 
of depressive symptoms, health-related quality of life (HRQL), 
illness-related stress, and clinical severity of psoriasis using 
validated scales.  Results: Thirty-two percent of all partici-
pants screened positive for depression. We observed a grad-
ed relationship between depressive symptoms and HRQL 
impairment (p  ! 0.001). Only 16.5% of those with high de-
pression scores were currently treated for depression. Both 
dissatisfaction with antipsoriatic treatment and illness-relat-
ed stress were highly associated with depression. After ad-
justment for HRQL, patients with more severe psoriasis were 
less likely depressed, although this association failed to 
reach statistical significance (multiadjusted odds ratio 0.37; 
95% CI 0.13–1.02; p = 0.06).  Conclusion: Patients with high 
subjective distress and low objective measures of psoriasis 
should be evaluated for depression. 
 Copyright © 2007 S. Karger AG, Basel 
 Received: July 14, 2006 
 Accepted: January 31, 2007 
 Jochen Schmitt, MD, MPH ,  Department of Dermatology
Medical Faculty Carl Gustav Carus, Technical University Dresden 
 Fetscherstrasse 74,  DE–01307 Dresden (Germany) 
 Tel. +49 351 458 2421, Fax +49 351 458 5326
E-Mail jochen.schmitt@uniklinikum-dresden.de 
 © 2007 S. Karger AG, Basel
1018–8665/07/2151–0017$23.50/0 
 Accessible online at:
www.karger.com/drm 
 Schmitt  /Ford  
 
Dermatology 2007;215:17–2718
goals, and social and subjective feelings of well-being. 
The growing number of studies that include HRQL as an 
outcome reflects the current broadening of the conceptu-
alization of psoriasis  [15] . Clinical symptoms only ac-
count for a relatively small proportion of the total vari-
ability in emotional well-being in psoriasis  [16] . Illness-
related stress – one of the dimensions of HRQL – is a 
particular problem for many patients with psoriasis. Ill-
ness-related stress mainly results from the anticipation of 
the reactions of others to psoriasis and adversely affects 
interpersonal activities  [17] . Despite substantial research 
on HRQL, illness-related stress, and clinical severity of 
psoriasis, it is not known which factors are present in the 
subset of patients in which the HRQL impairment is not 
reflected by the clinical severity.
 It has been reported that psoriasis has an impact on 
HRQL that is comparable to depression  [16] .
 However, a recent Italian study suggested that depres-
sion itself plays a considerable role in the overall morbid-
ity of psoriasis patients  [18] . Demoralization and dissat-
isfaction with treatment may contribute to depression. 
Depression affects treatment adherence and also modi-
fies the perception of pruritus, a typical symptom of pso-
riasis  [19, 20] .
 Although it has been proposed that depression plays a 
role in how psoriasis affects quality of life, primary data 
from the US population have not been published. We as-
sessed adult psoriasis patients from the US population on 
HRQL, clinical disease severity, illness-related stress, 
treatment satisfaction, and depression. The aim of this 
study was to investigate what factors account for de-
creased HRQL in psoriasis patients. We hypothesized 
that depressive symptoms might explain a substantial 
proportion of the total variance in HRQL in psoriasis pa-
tients. We further speculated that depression might be 
associated with the high HRQL impairment in a sub-
group of patients with clinically mild psoriasis. 
 Methods 
 Setting and Study Population 
 In order to efficiently perform a population-based study on 
factors that account for decreased HRQL in adults suffering from 
psoriasis we conducted this cross-sectional study through the In-
ternet. Patients 18 years or older with self-reported psoriasis who 
accessed the Internet from the US were eligible. This was techni-
cally possible through registration of the Internet protocol ad-
dress of the user, which provides information about the geograph-
ical region from which the Internet is accessed. Study subjects 
were recruited between January and May 2005. Recruitment in-
cluded an advertisement at google.com that appeared on the 
screen when ‘psoriasis’ or related search terms were entered. The 
exact wording and size of the advertisement was: ‘Johns Hopkins 
Study: Psoriasis & Quality of Life – 30 min Questionnaire – get 
your report back’. By clicking the web link of the advertisement, 
participants could enter the interactive study Internet page. A to-
tal of 361 patients were recruited, 74% (n = 267) of which com-
pleted the entire study questionnaire. All participants provided 
informed consent before starting to answer the study question-
naires. After finishing the questionnaires, participants received 
standardized feedback on their HRQL score and likelihood of de-
pression. Persons with high and moderately high probability of 
depression were instructed to seek further advice from a health 
professional. Additionally, the investigators’ contact information 
as well as resources for additional information on psoriasis and 
depression were provided.
 Approval from the Office for Research Subjects, Johns Hop-
kins Bloomberg School of Public Health, Baltimore, Md., was re-
ceived prior to initiating the study.
 Assessments 
 HRQL was assessed with the Dermatology Life Quality Index 
(DLQI), a widely used instrument with adequate psychometric 
properties (e.g. validity, reliability, sensitivity to change)  [21–23] . 
It consists of 10 questions considering the following domains: 
symptoms and feelings, daily activities, leisure, work and school, 
personal relationships, and the effects of treatment on daily life. 
Depression is not assessed in this instrument. The DLQI score 
ranges from 0 to 30 with higher scores reflecting worse quality of 
life  [21, 23] .
 The Center for Epidemiologic Study Depression Scale (CES-
D) is a 20-question instrument to assess symptom severity of de-
pression  [24] . It has been validated in different settings and has 
already been used in an Internet study  [24–27] . The CES-D score 
ranges from 0 to 60 with higher scores indicating higher likeli-
hood of depression. A common cutoff for a positive test is a score 
greater than 16. At this level, sensitivity ranges from 86 to 100%, 
and specificity from 84 to 53% in different studies  [24, 28, 29] . 
Because of the relatively high false-positive rate seen in patients 
with medical conditions, we created three levels of probability of 
depression: low-to-moderate probability (score  ! 16), moderate-
to-high probability (score 16–21), and high-to-very high proba-
bility (score  6 22)  [25] .
 Illness-related stress was measured using the Psoriasis Life 
Stress Inventory (PLSI), a psoriasis-specific instrument with ex-
cellent psychometric properties  [30, 31] . The PLSI consists of 15 
pairs of questions. The first asks whether a potentially stressful 
feeling or situation related to psoriasis was encountered within 
the past 4 weeks (e.g. people commenting on their skin lesions, 
people avoiding physical contact). If such an event was encoun-
tered, the participant is also asked to score the degree of stress 
experienced because of this situation on a 4-point Likert scale. 
The PLSI ranges from 0 to 45 with higher scores reflecting higher 
levels of illness-related stress. As proposed by the developers of 
the scale, we used a score of 10 as a cutoff to define high stress 
 [30] .
 The self-administered Psoriasis Area and Severity Index
(SAPASI) is a patient-rated instrument with adequate psychomet-
ric properties to assess the clinical severity of psoriasis  [32–36] . 
To be applicable in the Internet setting, the SAPASI was slightly 
modified: as in the original version, patients rated the intensity of 
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erythema, induration, and scaliness on a 12-cm visual analogue 
scale (VAS)  [34] . For estimation of the involved body surface area 
(BSA), patients were informed that the area of their palmar hand 
equals roughly 1% of their BSA. Participants then were asked to 
estimate the percentage of their body covered with psoriatic 
plaques. As in the original PASI, the percent BSA involvement was 
recategorized into a semiquantitative score with 0 indicating no 
BSA involvement, 1 = 1–9%, 2 = 10–29%, 3 = 30–49%, 4 = 50–
69%, 5 = 70–89% and 6 = 90–100%  [37] . The SAPASI was calcu-
lated using the formula: [(VAS-erythema + VAS-scaliness + VAS-
induration)/3]  BSA score.
 The SAPASI score ranges from 0 to 72 with higher scores in-
dicating higher clinical disease severity. Severe psoriasis was de-
fined as SAPASI  1 12, a score between 7 and 12 as moderate pso-
riasis, and a score of less than 7 as mild psoriasis. 
 Information on sociodemographic characteristics included 
age, sex, ethnicity, annual household income, education level, 
marital status, and living arrangements. Smoking status and cur-
rent alcohol use were also measured. Information on specific dis-
ease characteristics of psoriasis included age at onset, diagnosis 
by physician, joint involvement, current treatment, presence/ab-
sence of facial and genital lesions within the past 14 days, family 
history of psoriasis, and global severity rating of psoriasis within 
the past 14 days on a 5-point Likert scale. Participants were also 
asked to indicate their satisfaction with current antipsoriatic 
treatment, and to rate the intensity of pruritus caused by psori-
atic lesions within the past 14 days on a VAS scale ranging from 0 
to 10. Information on personal history of depression and current 
antidepressive treatment was collected. To increase internal va-
lidity, participants were also asked to indicate whether they had 
answered all questions honestly and whether they had completed 
the study questionnaire more than once. Participants indicating 
they had not answered honestly or had participated more than 
once were excluded from the analysis. The questionnaire was de-
signed in a way that allowed proceeding to the next set of ques-
tions only if all previous questions had been answered. Therefore 
no data were missing for our analysis.
 Statistical Analysis 
 We first compared the 265 subjects who completed the entire 
study questionnaire with those who only partially completed the 
study questionnaire (n = 94) by sociodemographic characteris-
tics, disease characteristics of psoriasis, personal history/current 
treatment of depression, smoking status, and alcohol abuse to ex-
plore the presence of possible selection bias.    2  test and Fisher’s 
exact test were used for binary variables. Wilcoxon rank-sum tests 
were performed for continuous variables due to positively skewed 
distributions  [38] .
 The population for the main analysis consisted of the 265 in-
dividuals who had complete observations. Spearman correlation 
coefficients were calculated to describe the univariate association 
of DLQI, CES-D, PLSI, and SAPASI. Univariate and multivariate 
analyses were performed to describe factors associated with 
HRQL impairment and the likelihood of depression. A DLQI of 
10 and a CES-D of 22 were used as cutoffs  [23–25] . Univariate 
analyses included Wilcoxon rank-sum,    2 , and Fisher’s exact tests, 
as appropriate. Separate multivariate logistic regression models 
were fitted to predict HRQL (DLQI) and the severity of depressive 
symptoms (CES-D). Independent variables for CES-D included 
sociodemographic characteristics, DLQI, SAPASI, pruritus, pres-
ence of genital/facial psoriatic lesions, and alcohol abuse. Impor-
tant covariates considered for the prediction of HRQL included 
sociodemographic characteristics, CES-D, SAPASI, presence of 
genital/facial lesions, pruritis and alcohol abuse. The fit of the fi-
nal models was assessed by Hosmer-Lemeshow    2  tests  [38] .
 The study web page was programmed in PERL 5. Javascript 
was used for real-time data analysis. The data were recorded in an 
SQL database and transferred to Stata statistical software 8.0 for 
Windows, which then was used to perform the statistical analysis 
 [39] .
 Results 
 Of the 361 participants who started answering the 
questionnaires, 267 (74%) completed the study. Two par-
ticipants (0.7%) indicated that they did not answer all 
questions honestly and therefore were excluded from the 
analysis. There were no statistically significant differenc-
es between participants who completed the study and 
those who did not with respect to age, gender, socioeco-
nomic status, disease characteristics of psoriasis, person-
al history and current treatment of depression, smoking 
status, and alcohol abuse ( table 1 ). Whites were more 
likely to complete the study questionnaire compared to 
other ethnic groups (p = 0.006). A higher dropout rate, 
particularly at the beginning of the study questionnaire, 
was found for each nonwhite ethnic group (data not 
shown). Patients with non-physician-diagnosed psoriasis 
were less likely to complete the survey (85 vs. 96%; p = 
0.001). 
 The following results are based on 265 complete ob-
servations. The majority of the sample was female, pre-
dominately white and less than 50% had completed a col-
lege education. Eleven participants (4.1%) did not report 
to have physician-diagnosed psoriasis. Thirty-one per-
cent (n = 84) screened positive for depression when using 
the conservative (CES-D  6 22) and 48.7% (n = 129) when 
using the conventional cutoff (CES-D  1 16). The mean 
DLQI score was 10.8 ( 8 7.1) with 50.3% (n = 133) scoring 
in the high HRQL impairment (DLQI  6 10) category. The 
mean PLSI score was 9.5 ( 8 9.5). About half of the patients 
(48.7%, n = 129) were classified as having clinically mild, 
24.5% (n = 65) moderately severe, and 26.8% (n = 71) se-
vere psoriasis (SAPASI 9.9  8 9.4).
 HRQL, depressive symptoms, and psoriasis-related 
stress were highly interrelated with correlation coeffi-
cients between 0.58 and 0.81 (p  ! 0.001 for each combina-
tion). Statistically significant correlations were also found 
between clinical severity of psoriasis and patient ratings 
of depression and HRQL ( table 2 ).
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 Factors Associated with HRQL 
 Among patients with high HRQL impairment, 51.9% 
(n = 69) screened positive for depression using a conserva-
tive cutoff (CES-D  6 22) and were 5 times more likely to 
screen positive than those with low HRQL impairment. 
 The mean CES-D in the subgroup with high HRQL 
impairment was 24.0 compared to 11.7 in participants 
with lower HRQL (p  ! 0.001). The subgroup of patients 
with high HRQL impairment reported having encoun-
tered significantly more potentially stressful situations re-
lated to their psoriasis, and also experienced significantly 
more illness-related stress in the past 28 days (mean PLSI 
15.5  8 9.5 vs. 3.5  8 4.3; p  ! 0.001) ( table 3 ).
Table 1. Comparison of sociodemographic characteristics of participants who completed the study versus those 
who did not complete the study (n = 359)
Variable Participants
who completed
questionnaire
Participants who
did not complete
questionnaire
z/2 a p value
n = 265 n = 94b
Gender, % females 63.4 72.3 2.46 0.12
Age (mean 8 SD), years 42.6813.3 40.7815.7 1.29 0.20
Annual household income <USD 30,000, % 22.3 29.8 2.14 0.14
Race, % white 91.3 78.7 10.44 0.006
Education level, %
No degree 7.6 10.7 4.02 0.13
High school 46.8 55.3
College 44.7 34.0
Living alone, % 14.3 10.6 0.821 0.37
Married, % 60.4 59.3 0.056 0.81
n = 265 n = 64c
Diagnosis of psoriasis by physician, % 95.9 84.4 11.36 0.001
Diagnosis of psoriatic arthritis by physician, % 21.1 23.4 0.16 0.69
Age at onset of psoriasis (mean 8 SD), years 27.4815.6 26.3814.1 0.15 0.88
Severity rating of psoriasis, % severe 42.6 39.1 0.27 0.60
Positive personal history for depression, % 33.6 27.7 0.35 0.55
Currently treated against depression, % 15.9 17.2 0.07 0.79
n = 265 n = 49d
Positive family history for psoriasis, % 39.3 32.7 0.76 0.38
Rating of overall health state, % poor or fair 27.6 18.4 1.81 0.18
Medications (mean 8 SD) 1.682.0 1.281.5 1.13 0.26
Current smoking, % 44.5 35.4 1.38 0.24
Alcohol (mean 8 SD), days having 6 or more drinks
within past month 3.186.6 3.386.8 0.31 0.76
a Wilcoxon rank-sum test, 2 test (as appropriate).
b Patients who completed page 1 of the study questionnaire.
c Patients who completed page 2 of the study questionnaire.
d Patients who completed page 3 of the study questionnaire.
Table 2. Correlation matrix (Spearman correlation coeffi  cients of 
DLQI, CES-D, PLSI, and SAPASI; n = 265)
DLQI CES-D PLSI SAPASI
DLQI 1.00
CES-D 0.58 1.00
PLSI 0.81 0.68 1.00
SAPASI 0.61 0.33 0.56 1.00
p < 0.001 for each combination.
 Depressive Symptoms and Quality of Life 
in Psoriasis 
Dermatology 2007;215:17–27 21
 Younger age, lower annual family income, and current 
smoking were also associated with high HRQL impair-
ment. Forty-four percent of the patients with high DLQI 
scores were classified as having clinically severe psoriasis, 
as compared to 9.1% of the patients with lower HRQL im-
pairment (p  ! 0.001). Facial and genital psoriatic lesions, 
as well as the intensity of pruritus within the past 14 days 
were strong predictors for decreased HRQL (p  ! 0.001 for 
each). There were no differences by HRQL impairment 
regarding receipt of antipsoriatic treatment. However, 
Table 3. Comparison of sociodemographic characteristics, disease characteristics and psychosocial comorbidity of participants by 
HRQL impairment (DLQI ≥10 vs. DLQI <10; n = 265)
Variable Total
(n = 265)
Higher HRQL
impairment
(DLQI ≥10)
(n = 133)
Lower HRQL
impairment
(DLQI <10)
(n = 132)
z/2 * p value
Sociodemographics
Gender, % females 63.4 66.2 60.6 0.88 0.35
Age (mean 8 SD), years 42.5813.3 40.0812.2 45.2814.0 3.21 0.002
Annual household income <USD 30,000, % 22.3 30.1 14.4 9.41 0.002
Race, % white 91.3 92.5 90.2 0.45 0.50
Education level, %
No degree 7.6 9.8 5.3
High school 46.8 47.4 46.2 2.23 0.33
College 45.7 42.9 48.5
Living alone, % 14.3 15.0 13.6 0.11 0.75
Current smoking, % 44.5 55.6 33.3 13.34 <0.001
Alcohol (mean 8 SD), days having 6 or more drinks within past month 3.186.6 3.887.7 2.385.2 1.40 0.16
Characteristics of psoriasis
Objective severity (SAPASI; mean 8 SD) 9.989.4 14.2810.4 5.685.7 7.54 <0.001
Mild (SAPASI <7), % 48.7 25.5 72.0
Moderate (SAPASI 7–12), % 24.5 30.1 18.9 63.4 <0.001
Severe (SAPASI >12), % 26.8 44.4 9.1
Psoriatic arthritis, % 21.1 27.1 15.2 5.64 0.02
Psoriatic lesions on face within past 14 days, % 33.6 40.6 26.5 5.89 0.02
Psoriatic lesions on genitals within past 14 days, % 41.5 57.1 25.8 26.88 <0.001
Pruritus of psoriatic lesions within past 14 days (VAS; mean 8 SD) 5.782.9 6.982.5 4.582.8 6.74 <0.001
Antipsoriatic treatment within past 14 days, %
None 22.6 19.6 25.8
Topical 55.9 57.9 53.8 2.33 0.51
Systemic 15.5 15.0 15.9
Phototherapy 6.4 7.5 4.6
Satisfaction with treatment within past 14 days, %
Satisfied 7.2 1.5 12.9
Undecided 28.3 20.3 36.4 25.71 <0.001
Dissatisfied 64.5 78.2 50.8
Psychosocial and psychiatric comorbidity
Positive personal history for depression, % 33.6 41.4 25.8 7.22 0.007
Currently treated against depression, % 15.9 16.5 15.2 0.10 0.76
CES-D score
Total (mean 8 SD) 17.8813.2 24.0813.4 11.789.8 8.21 <0.001
Depression screening, %
Positive, CES-D >16 48.7 70.7 26.5 51.72 <0.001
Highly positive, CES-D ≥22 31.7 51.9 11.4 50.23 <0.001
Illness-related stress (PLSI; mean 8 SD) 9.589.5 15.589.5 3.584.3 8.21 <0.001
* Wilcoxon rank-sum test, 2 test (as appropriate).
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those with high HRQL impairment were more likely to 
indicate they were dissatisfied with their current treat-
ment for psoriasis ( table 3 ). 
 Figure 1 shows the likelihood of depression stratified 
by HRQL tertiles. A clear dose-response relationship be-
tween depressive symptoms and HRQL impairment was 
observed (p values for trend  ! 0.001 for all strata). More 
than 70% of the participants in the highest DLQI tertile 
had a positive depression screen at the higher CES-D cut-
off ( fig. 1 ).
 In the final multiadjusted logistic regression model 
predicting HRQL, depressive symptoms (CES-D), clini-
cal severity of psoriasis (SAPASI), presence of genital le-
sions, and intensity of pruritus were positively and inde-
pendently associated with HRQL impairment ( table 4 ). 
Age, gender, and annual household income were includ-
ed in the final multivariate logistic regression (MLR) 
model due to results from the univariate analysis and 
considerations regarding potential confounding. The ad-
justed odds ratio of high HRQL impairment for partici-
pants with a CES-D score of 21 or more compared to 
those with lower likelihood of depression (CES-D  ! 16) 
was 6.16 (95% CI 2.80; 13.55; p  ! 0.001).
 Factors Associated with Positive Depression
Screening Test  
 Younger age, lower annual family income, current 
smoking, and alcohol abuse were positively associated 
with a higher likelihood of depression ( table 5 ). Clinical 
severity of psoriasis was also positively associated with 
0
10
20
30
40
50
60
70
80
%
48.5
39.7
11.8
Low likelihood of depression
(CES-D <16)
31.1
8.3
31.1
20.2
37.8
71.4
Higher likelihood of depression
(CES-D 16–21)
High likelihood of depression
(CES-D >21)
Low HRQL impairment (DLQI <7) (n = 87)
Moderate HRQL impairment (DLQI 7–12) (n = 85)
High HRQL impairment (DLQI >12) (n = 93)
 Fig. 1. Likelihood of depression for par-
ticipants by HRQL impairment (n = 265). 
 * p value for trend  ! 0.001 for all strata. 
Covariate OR 95% CI p value
Likelihood of depression
Low (CES-D <16) reference
Moderate (CES-D 16–21) 1.94 0.86; 4.39 0.11
High (CES-D >21) 6.16 2.80; 13.55 <0.001
Objective severity of psoriasis
Mild (SAPASI <7) reference
Moderate (SAPASI 7–12) 2.41 1.13; 5.14 0.02
Severe (SAPASI >12) 6.64 2.82; 5.14 <0.001
Genital lesions 1.97 1.01; 3.83 0.05
Pruritus of psoriatic lesions (VAS)a 1.21 1.07; 1.37 0.002
Hosmer-Lemeshow 212 (p value) 10.18 (0.43)
Adjusted for age, gender, and annual household income.
a Modeled as continuous covariate.
Table 4. Multi-adjusted logistic regression 
on HRQL (DLQI ≥10; n = 265)
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higher likelihood of depression (SAPASI 14.0  8 11.7 vs. 
8.0  8 7.4; p  ! 0.001). Other clinical characteristics of pso-
riasis that were found positively associated with a positive 
depression score included presence of genital lesions and 
intensity of pruritus (p  ! 0.001 for each). Dissatisfaction 
with antipsoriatic treatment was higher in patients who 
screened positive for depression (p  ! 0.001). The sub-
group of patients with a positive depression score had sig-
nificantly more HRQL impairment (DLQI 16.6  8 6.8 vs. 
5.8  8 6.4; p  ! 0.001) and had also experienced more ill-
ness-related stress in the past 28 days (PLSI 17.7  8 10.0 
vs. 3.5  8 4.3; p  ! 0.001) ( table 5 ).
 In the final multivariate model on depressive symp-
toms, HRQL (DLQI), illness-related stress (PLSI), and 
genital lesions were independent positive predictors ( ta-
ble 6 ). A qualitative change in the direction of the rela-
Table 5. Comparison of sociodemographic characteristics, disease characteristics and psychosocial comorbidity of participants by 
likelihood of depression (CES-D ≥22 vs. CES-D <22; n = 265)
Variable Total 
(n = 265)
Higher likelihood 
of depression 
(CES-D ≥22)
(n = 84)
Lower likelihood 
of depression 
(CES-D ≥22) 
(n = 181)
z/2 * p value
Sociodemographics
Gender, % females 63.4 66.7 61.9 0.57 0.45
Age (mean 8 SD), years 42.5813.3 44.6812.2 38.3814.0 3.76 <0.001
Annual household income <USD 30,000, % 22.3 35.7 16.0 12.86 <0.001
Race, % white 91.3 90.5 91.7 0.11 0.74
Education level, %
No degree 7.6 9.5 6.6
High school 46.8 48.8 45.9 1.17 0.56
College 45.7 41.7 47.5
Living alone, % 14.3 14.3 14.4 0.01 0.99
Current smoking, % 44.5 65.5 34.5 21.85 <0.001
Alcohol (mean 8 SD), days having 6 or more drinks within past month 3.186.6 4.485.2 2.485.6 2.03 0.04
Characteristics of psoriasis
Objective severity (SAPASI) (mean 8 SD) 9.989.4 14.0811.7 8.087.4 4.16 <0.001
Mild (SAPASI <7), % 48.7 11.0 56.9
Moderate (SAPASI 7–12), % 24.5 37.3 23.2 18.50 <0.001
Severe (SAPASI >12), % 26.8 41.7 19.9
Psoriatic arthritis, % 21.1 25.0 19.3 1.10 0.29
Psoriatic lesions on face within past 14 days, % 33.6 41.6 29.8 3.60 0.06
Psoriatic lesions on genitals within past 14 days, % 41.5 63.1 36.9 23.60 <0.001
Pruritus of psoriatic lesions within past 14 days (VAS) (mean 8 SD) 5.782.9 6.882.5 5.283.0 4.23 <0.001
Antipsoriatic treatment within past 14 days, %
None 22.6 15.6 26.0
Topical 55.9 55.3 57.1 13.08 0.004
Systemic 15.5 14.3 16.2
Phototherapy 6.4 13.1 2.8
Satisfaction with treatment within past 14 days, %
Satisfied 7.2 2.4 9.4
Undecided 28.3 19.0 32.6 11.40 0.003
Dissatisfied 64.5 78.6 58.1
Psychosocial and psychiatric comorbidity
Positive personal history for depression, % 33.6 60.7 21.0 40.58 <0.001
Currently treated against depression, % 15.9 22.6 12.7 4.23 0.04
Quality of life (DLQI) (mean 8 SD) 10.887.1 16.686.8 5.886.4 8.16 <0.001
Illness-related stress (PLSI) (mean 8 SD) 9.589.5 17.7810.0 3.584.3 9.22 <0.001
* Wilcoxon rank-sum test, 2 test (as appropriate). 
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tionship after multivariate adjustment was observed for 
clinical severity of psoriasis. After adjustment, lower
SAPASI scores were associated with higher CES-D scores. 
The relative odds of a positive depression screening test 
for participants with severe clinical psoriasis was 0.37 
(95% CI 0.13;  1.02; p = 0.06) compared to participants 
with mild clinical psoriasis ( table 6 ). This was probably 
due to collinearity between HRQL, illness-related stress, 
and clinical severity of psoriasis. A dose-response rela-
tionship was observed for DLQI, PLSI, and SAPASI ( ta-
ble 6 ). 
 Depression was undertreated in the participants of 
this sample. Sixty percent of those who screened positive 
for depression reported being told by a health profession-
al that they had depression at some point in their lives. 
Only 23% of those who screened positive for current de-
pression also reported currently receiving treatment for 
depression.
 Discussion 
 The present study highlights the critical role of depres-
sion in the overall morbidity of patients suffering from 
psoriasis. Using the standard cutoff for depression on the 
CES-D, nearly half of all psoriasis patients, and nearly 
three quarters of the subgroup with high HRQL impair-
ment had a positive depression screening test. Even when 
applying a more conservative measure of depression with 
higher specificity, half of those with high HRQL impair-
ment tested positive for depression. 
 An important advantage of collecting data over the 
Internet is that participants are more likely to disclose 
private issues and harmful health behavior. Collecting 
information on psychiatric morbidity, stress and social 
anxiety, and the presence of genital lesions via the Inter-
net may result in data with higher validity compared to 
other methodologies  [40, 41] . Another advantage of an 
Internet-recruited sample is that patients from all differ-
ent geographical regions within the US could easily par-
ticipate. Additionally, the Internet setting offered very 
high efficiency both in terms of monetary resources and 
time. For both the Internet and the US healthcare sys-
tem, significant ethnic and socioeconomic disparities 
exist regarding access  [42–44] . It is possible that patients 
who are more frustrated with their psoriasis were more 
likely to take the time to respond to the advertisement 
and to complete the questionnaire, so that a recruitment 
bias cannot be excluded. The recruitment ad on google.
com did not include any mention of depression or low 
social functioning. Although this is a general problem 
associated with surveys rather than a specific disadvan-
tage of an Internet-based study, our results should be in-
terpreted with caution, particularly with respect to gen-
eralization to the general US population. As in other in-
ternet-based studies, females appeared to be more likely 
and ethnic minorities less likely to participate  [25] . In 
our study, participants belonging to ethnic minorities 
Covariate OR 95% CI p value
Impairment of health-related quality of life
Low (DLQI <7) reference
Moderate (DLQI 7–12) 1.61 0.54; 4.79 0.39
High (DLQI >12) 5.32 1.54; 18.27 0.008
Illness-related stress
Low (PLSI <4) reference
Moderate (PLSI 4–12) 2.81 0.99; 8.01 0.05
High (PLSI >12) 8.08 2.40; 27.24 0.001
Objective severity of psoriasis
Mild (SAPASI <7) reference
Moderate (SAPASI 7–12) 0.45 0.18; 1.15 0.10
Severe (SAPASI >12) 0.37 0.13; 1.02 0.06
Genital lesions 2.35 1.15; 4.80 0.02
Pruritus of psoriatic lesions (VAS)b 1.07 0.93; 1.23 0.35
Hosmer-Lemeshow 212 (p value) 14.78 (0.14)
a Adjusted for age, gender, and annual household income. 
b Modeled as continuous covariate.
Table 6. Multi-adjusteda logistic 
 regression on depression (CES-D ≥22;
n = 265)
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were more likely to drop out. As this study consisted of 
many different web pages which all needed to be down-
loaded on the computer, this high early dropout rate 
might be associated with the use of slower dial-up mo-
dems and long waiting times when proceeding through 
the questionnaires. With respect to HRQL impairment 
and depression, however, this selection bias is likely to be 
nondifferential. 
 An additional possible limitation of the study are 
questions concerning the validity of a self-reported diag-
nosis of psoriasis. Almost all of the study subjects re-
ported that psoriasis was diagnosed by a physician. It 
cannot be ruled out that some participants did not truly 
have psoriasis. However, in another sample of psoriasis 
patients, Shikiar et al.  [45]  observed high construct va-
lidity of self-reported data both with respect to each oth-
er and to clinical assessments. In order to be applicable 
for the Internet setting we used a modified version of the 
SAPASI with direct estimation of BSA involvement. The 
distribution in our sample of the SAPASI was 9.9  8 9.4, 
which is almost identical to the distribution of the 
SAPASI in its validation study  [34] . DLQI and PLSI both 
are instruments with adequate psychometric properties, 
but have not been validated in an Internet setting before. 
The observed distributions of the DLQI and PLSI scores 
were highly similar to the distributions observed in oth-
er settings  [23, 30] . The CES-D has already been used in 
an Internet setting as a screening instrument for depres-
sion  [25] . Overall, the quality of the collected data is 
therefore considered high, particularly with regard to in-
ternal validity. However, it is possible that patients with 
higher HRQL impairment and/or higher illness-related 
stress overestimate the clinical features of their psoriasis, 
e.g. erythema, induration, or scaliness. In the presence 
of such a differential information bias the true associa-
tion between clinical severity of psoriasis and HRQL im-
pairment would be even weaker. Consequently, the true 
relative impact of depression in the causal model of 
HRQL impairment in psoriasis might be even greater 
than what we observed.
 To our knowledge this is the first study that has con-
sidered depression and illness-related stress when inves-
tigating factors associated with decreased HRQL in pso-
riasis patients  [4, 16, 46–50] . Between 20 and 25% of
people with chronic medical conditions will become de-
pressed during the course of their disease  [51] . We also 
found a much higher rate of depression in our sample of 
individuals with a chronic disease compared to the gen-
eral population. Studies on suicidal ideation in patients 
suffering from psoriasis have found rates between 2.5 
and 9.7%  [52, 53] . These figures are at least as high as 
what has been reported from other chronic medical con-
ditions, and much higher than in the general population 
 [54, 55] . The only randomized controlled trial that ex-
amined antidepressive pharmacological interventions 
in 60 psoriasis patients found a beneficial effect of mo-
clobemide, a reversible inhibitor of monoamine oxidase 
type A on objective severity of psoriasis and depressive 
symptoms  [56] . Lithium, however, is a well-known trig-
ger for psoriasis. Exacerbations of psoriasis related to 
fluoxetine and bupropion have also been described  [57–
59] .
 The mismatch of objective and subjective severity of 
psoriasis in a subset of patients has been extensively dis-
cussed in the recent dermatological literature  [12, 60–62] . 
The present study suggests that this mismatch might be 
explained by prevalent depression. 
 The positive crude association between CES-D and 
SAPASI ( table 2 ) not only disappeared after adjustment 
for DLQI, but qualitatively changed (positive relationship 
in crude estimate  ] negative relationship in adjusted es-
timate) ( table 6 ). Based on this finding we hypothesize 
that in a subset of patients with psoriasis, dissatisfaction 
with treatment, chronic problems in everyday life, and 
(presumably) inadequate coping strategies can cause de-
pression, even though psoriasis may clinically not be se-
vere. As psoriasis does not appear to directly involve the 
brain except possibly through inflammatory markers it 
seems plausible that the chronicity of the condition may 
lead to depression primarily through HRQL impairment. 
However, this hypothesis is based on a cross-sectional da-
taset, where causal relationships cannot be established. 
We also cannot rule out recruitment bias; our findings 
should, therefore, be confirmed in a different setting and 
in a prospective study before generalization. There is sub-
stantial evidence that dermatologists often do not detect 
psychiatric comorbidity  [63–65] . Lack of attention to 
psychiatric comorbidity may contribute to the observed 
high rate of dissatisfaction with current antipsoriatic 
treatment. Almost two thirds of all patients, and 78.6% of 
those with a high likelihood of depression expressed dis-
satisfaction with their antipsoriatic treatment. Our data 
indicate that less than half of the patients with psoriasis 
and depression are receiving any treatment for depres-
sion. 
 The data presented highlight that depression might 
play a critical role in the life of psoriasis patients. We 
found that concurrent depression affects HRQL of pa-
tients suffering from psoriasis at least as much as the clin-
ical severity of their psoriasis. Most of these psoriasis pa-
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tients with depression also indicated a lot of stress experi-
ences related to their psoriasis and dissatisfaction with 
psoriasis treatment. Depression might also at least par-
tially account for the frequently observed mismatch of 
objective and subjective severity of psoriasis. Depression 
appears undertreated, suggesting that integrated treat-
ment models including dermatologists, primary care 
physicians and mental health specialists might be most 
effective. Our findings suggest that not only antidepres-
sants, but also enhancing coping strategies might help 
depressed psoriasis patients to improve their HRQL. This 
appears to be another situation where we need to develop 
and evaluate models of care that address all the needs of 
patients.
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